Xarelto, one of the newer generation of blood thinners, was approved by the FDA in 2011. It’s making news lately — and not for good reason. Lawsuits alleging rivaroxaban (Xarelto) harms — or even kills — keep piling up. Moreover, the FDA has concerns about the testing device used in the clinical trials that led to approval of the drug. If you’re taking this anticoagulant or one of its cousins — apixaban (Eliquis), edoxaban (Savaysa) and dabigatran (Pradaxa) — that are mainly prescribed to treat atrial fibrillation to prevent blood clots potentially causing a stroke, should you continue? While many…

Read More